Industry Survey Lays Bare Huge Disparities In Access To New Drugs In Europe
A new survey has shown wide differences in patient access to new medicines across, and even within, European countries, with time to access after drug approval ranging from 100 to 1,000 days. Industry has put the blame on factors such as duplicative clinical assessments, the length of HTA processes, and local formulary decisions.
You may also be interested in...
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”
Two documents published by the European Commission outline proposals to prepare for future health emergencies such as pandemics and the impact of antimicrobial resistance, with next-generation vaccines and novel or repurposed therapeutics high on the agenda.